Item 8.01 Other Events.
OnJanuary 6, 2022 ,Avalo Therapeutics, Inc. released an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Also onJanuary 6, 2022 , the Company issued a press release announcing positive Phase 1b Results for AVTX-002 in moderate to severe Crohn's disease patients and additional program updates, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits: Exhibit No. Description 99.1 Investor Presentation. 99.2 Press Release, datedJanuary 6, 2022 . 104 The cover pages of this Current Report on Form 8-K,
formatted in Inline XBRL. 1
--------------------------------------------------------------------------------
© Edgar Online, source